Eloralintide vs. Retatrutide: A Different Way to Target Weight Loss
Eloralintide targets amylin receptors, while retatrutide—often called “reta”—targets GLP-1, GIP and glucagon receptors. Both are investigational medicines being developed for obesity, but they approach appetite and metabolic regulation through different biological pathways. Eloralintide is also being studied alongside tirzepatide, creating a combination that brings amylin into the incretin treatment strategy. lilly.com
For people following the next generation of weight-loss drugs, that distinction matters. A treatment can produce substantial weight loss without activating the same receptors as its competitors. Understanding which signals each medicine targets helps explain why researchers are developing both—and why declaring one the winner requires more than comparing headline percentages.
What Is Eloralintide?
Eloralintide is Lilly’s investigational, once-weekly injectable amylin receptor agonist. It is designed to reproduce selected effects of amylin, a hormone involved in the body’s response to eating. Its intended benefit is to strengthen feelings of fullness and reduce calorie intake through a pathway distinct from GLP-1 and GIP. Lilly is investigating eloralintide both as a standalone treatment and in combination with tirzepatide. lilly.com
That makes eloralintide particularly interesting in a field dominated by incretin therapies. It offers researchers another biological target for addressing hunger, rather than simply increasing activity at the receptors already used by existing medicines.
How Is Retatrutide Different?
Retatrutide combines activity at three receptors in a single molecule: GLP-1, GIP and glucagon. GLP-1 and GIP are involved in appetite and glucose regulation, while glucagon adds a different metabolic component. Glucagon receptor activity is being investigated partly because of its potential contribution to energy expenditure and changes in liver metabolism. Exactly how much each pathway contributes to retatrutide’s effects in humans remains an active research question. PubMed
Eloralintide alone therefore should not be described as another triple agonist. Its defining target is amylin. The three-pathway comparison becomes relevant when eloralintide is combined with tirzepatide.
How Much Weight Loss Has Eloralintide Produced?
In a 48-week Phase 2 trial involving 263 adults with obesity or overweight and a related health condition, without type 2 diabetes, the highest fixed-dose eloralintide group achieved an average 20.1% reduction in body weight, compared with 0.4% with placebo. These were efficacy-estimand results, estimating outcomes had participants remained on treatment, with possible interruptions or dose adjustments. The study was published in The Lancet. Eli Lilly and Company
For context, retatrutide’s published Phase 2 obesity trial reported average weight loss of 24.2% at 48 weeks in its highest-dose group, compared with 2.1% with placebo. These are findings from separate studies, not a direct comparison between the drugs. They cannot establish that one treatment would outperform the other in the same patients. PubMed
Why Combining Eloralintide With Tirzepatide Is Getting Attention
The combination tests whether adding amylin receptor activity can improve results beyond targeting GLP-1 and GIP alone. In September 2026, Lilly reported that the highest-dose EloraTZP group achieved 23.3% average weight loss at 48 weeks, compared with 14.8% with tirzepatide alone, in a Phase 2b trial involving adults with overweight or obesity and type 2 diabetes. These were also efficacy-estimand results. Eli Lilly and Company
The improvement came with a meaningful tolerability tradeoff. Across combination groups, 10.8% to 27.0% of participants discontinued treatment because of adverse events, compared with 2.9% in the tirzepatide group. Gastrointestinal events were more frequent with the combination. These sponsor-reported findings support further investigation, while showing why treatment persistence matters alongside weight loss. Eli Lilly and Company
Is Eloralintide Easier to Tolerate Than Reta?
That remains an open question. In eloralintide’s standalone Phase 2 trial, the most common adverse events included gastrointestinal symptoms and fatigue. These occurred more frequently at higher doses, and slower dose escalation reduced their incidence. A different receptor target does not mean a treatment is free of side effects. Eli Lilly and Company
Retatrutide’s Phase 2 trial also reported predominantly gastrointestinal adverse events, with tolerability affected by dose and starting regimen. Establishing whether eloralintide offers a better balance of effectiveness and tolerability requires comparative evidence, rather than impressions drawn from separate trial reports. New England Journal of Medicine
What About Retatrutide and Heart Rate?
Retatrutide’s published Phase 2 obesity trial reported dose-dependent increases in heart rate that peaked around week 24 and subsequently declined. The investigators noted that the increases were similar to those reported with GLP-1 receptor agonists. That makes it too simplistic to attribute the entire effect to glucagon receptor activity. New England Journal of Medicine
Eloralintide’s different receptor profile creates a reasonable question about how its cardiovascular effects might differ. However, receptor selection alone cannot establish that it is safer for the heart. That conclusion would require clinical evidence examining cardiovascular safety and outcomes.
Why This Research Matters
Eloralintide expands the possibilities for obesity treatment by bringing amylin into a rapidly developing therapeutic field. Its standalone results show that substantial weight loss can occur through this pathway, while combination research explores whether amylin and incretin therapies can provide additional benefit together. Eli Lilly and Company
For readers comparing eloralintide with reta, the useful questions extend beyond the largest percentage on a chart. How many people can remain on treatment? How durable are the results? What happens to physical function, body composition and long-term health? Those questions will determine how these medicines fit into future care.
Frequently Asked Questions
Is eloralintide a GLP-1 drug?
No. Eloralintide is a selective amylin receptor agonist. When combined with tirzepatide, the combination also includes GLP-1 and GIP receptor activity. lilly.com
Is eloralintide the same as EloraTZP?
No. Eloralintide is the amylin-targeting medicine. EloraTZP is the investigational combination of eloralintide and tirzepatide. lilly.com
Has eloralintide been shown to beat retatrutide?
The studies discussed here do not establish that. Eloralintide, its tirzepatide combination and retatrutide have been evaluated in different trial settings. A reliable ranking requires stronger comparative evidence.